Explore the Global Long-Acting Implantable GLP-1 Obesity Devices Market— analysis of key trends, regional growth, top players, and a 10-year forecast from 2026 to 2036.

Future Market Insights

Long-Acting Implantable GLP-1 Obesity Devices Market

Key Insight

FMI opines the GLP-1 obesity implant market was valued at USD 59.1 million in 2025. The industry is expected to reach USD 76.0 million in 2026 and USD 932.9 million by 2036. Exenatide implants are poised to dominate by molecule type with 54.0% share in 2026, and 6-month implants are expected to lead by duration profile through the forecast period.

March 16, 2026

Anurag Sharma

250 Pages

Cite this Report

Long-Acting Implantable GLP-1 Obesity Devices Market

https://www.futuremarketinsights.com/reports/long-acting-implantable-glp-1-obesity-devices-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Ashland
Corbion
DelSiTech Ltd
Delpor
Evonik Health Care
Poly-Med Inc
Vivani Medical

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Long-Acting Implantable GLP-1 Obesity Devices Market

Key Players

Similar Industry Reports